Eyelid DermatitisEarly Phase 1NCT06684522
Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
A Early Phase 1 study testing Upadacitinib 15 MG in people with Eyelid Dermatitis, run by Northwestern University at 1 site in United States.
Trial summary
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Eyelid Dermatitis
- What is being tested?
- Upadacitinib 15 MG
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Dec 2025to Jun 2027
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Individuals age 18-70 years old with eyelid dermatitis for at least two months
- Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib)
- Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib.
- Willing and able participants that provide informed consent
- Willing and able participants that comply with study activities
Who cannot join
- Self-reported history of allergic response to upadacitinib
- Subject with self-reported history of heart disease, stroke, or neurological conditions
- Currently taking topical medications for eyelid dermatitis within one week of starting study drug
- Women who are pregnant, nursing, or who may become pregnant during the study
- Non-English-speaking subjects
- Patients with an active serious infection
Show all 9Show fewer
- Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment.
- Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb<8g/dL, ALC<500 cells/mm3 and ANC <1000 cells/mm3
- Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Northwestern University Department of Dermatology
Chicago, Illinois, 60611
Dermatology CTU, NUderm-research@northwestern.edu
About this study
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
- Conditions
- Eyelid Dermatitis
- Being tested
- Upadacitinib 15 MG
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Upadacitinib 15 MGDrug
Also called RINVOQ
Upadacitinib 15mg daily
| Study group | Role | What they receive |
|---|---|---|
| Upadacitinib Treatment | Experimental | Participants on upadacitinib 15mg daily Receives: Drug: Upadacitinib 15 MG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction in Investigator Global Assessment (IGA)
Reduction in baseline IGA score at week 12 compared to week 0
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2024
- Study start18 Dec 2025
- Primary completionJun 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Eyelid DermatitisStudies of the same condition, open and under way.
- More trials run by Northwestern UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Walter Liszewski, Northwestern University
- Investigators
- Walter Liszewski, Principal investigator, Northwestern University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06684522
- Sponsor's protocol ID
- STU00221561
- Status last verified
- May 2026
- First submitted
- 10 Nov 2024
- Last updated
- 26 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
- ClinicalTrials.gov ID
- NCT06684522
- Acronym / sponsor ID
- STU00221561
- Conditions
- Eyelid Dermatitis
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Northwestern UniversityUniversity, hospital or other
- Study start
- 18 Dec 2025 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 12 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Upadacitinib Treatment | Experimental | Drug: Upadacitinib 15 MGParticipants on upadacitinib 15mg daily |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Individuals age 18-70 years old with eyelid dermatitis for at least two months
- Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib)
- Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib.
- Willing and able participants that provide informed consent
- Willing and able participants that comply with study activities
Key exclusion criteria (9 listed)
- Self-reported history of allergic response to upadacitinib
- Subject with self-reported history of heart disease, stroke, or neurological conditions
- Currently taking topical medications for eyelid dermatitis within one week of starting study drug
- Women who are pregnant, nursing, or who may become pregnant during the study
- Non-English-speaking subjects
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Upadacitinib 15 MGAlso: RINVOQUpadacitinib 15mg daily | Drug | Upadacitinib Treatment |
Primary outcome
Reduction in Investigator Global Assessment (IGA)
Time frame: 12 weeks
Reduction in baseline IGA score at week 12 compared to week 0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2026.
Related trials for Eyelid Dermatitis
Active, not recruitingPhase 2
Autologous Serum Obtained by a Closed-Circuit Collection Device
GVHD, Meibomian Gland Dysfunction (Disorder)
RecruitingObservational study
Frequency of Palpebral Involvement in Adult With Atopic Dermatitis
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Walter Liszewski principal investigator
Northwestern University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Upadacitinib 15 MG in people with Eyelid Dermatitis, run by Northwestern University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dermatology CTU (312-503-5944, NUderm-research@northwestern.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction in Investigator Global Assessment (IGA) (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.